Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Identifieur interne : 000C21 ( Main/Exploration ); précédent : 000C20; suivant : 000C22Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Auteurs : Saverio Cinieri [Italie] ; Arlene Chan [Australie] ; Kadri Altundag [Turquie] ; An Vandebroek [Belgique] ; Nicole Tubiana-Mathieu [France] ; Agusti Barnadas [Espagne] ; Patricia Dodyk [Argentine] ; Silvia Lazzarelli [Italie] ; Michiel Botha [Afrique du Sud] ; Daniel Rauch [Suisse] ; Gustavo Villanova [France] ; Ugur Coskun [Turquie]Source :
- Clinical breast cancer [ 1938-0666 ] ; 2017.
Descripteurs français
- KwdFr :
- Administration par voie intraveineuse, Administration par voie orale, Adulte, Adulte d'âge moyen, Alopécie (), Antinéoplasiques antimétabolites (administration et posologie), Antinéoplasiques antimétabolites (effets indésirables), Antinéoplasiques antimétabolites (usage thérapeutique), Antinéoplasiques d'origine végétale (administration et posologie), Antinéoplasiques d'origine végétale (effets indésirables), Antinéoplasiques d'origine végétale (usage thérapeutique), Capécitabine (administration et posologie), Capécitabine (usage thérapeutique), Désoxycytidine (administration et posologie), Désoxycytidine (analogues et dérivés), Désoxycytidine (effets indésirables), Désoxycytidine (usage thérapeutique), Fatigue (), Femelle, Humains, Neutropénie (), Paclitaxel (administration et posologie), Paclitaxel (effets indésirables), Paclitaxel (usage thérapeutique), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Qualité de vie, Récepteur ErbB-2 (métabolisme), Résultat thérapeutique, Sujet âgé, Survie sans rechute, Taxoïdes (administration et posologie), Taxoïdes (effets indésirables), Taxoïdes (usage thérapeutique), Traitement néoadjuvant (), Tumeurs du sein (anatomopathologie), Tumeurs du sein (mortalité), Tumeurs du sein (métabolisme), Tumeurs du sein (traitement médicamenteux), Vinblastine (administration et posologie), Vinblastine (analogues et dérivés), Vinblastine (effets indésirables), Vinblastine (usage thérapeutique).
- MESH :
- administration et posologie : Antinéoplasiques antimétabolites, Antinéoplasiques d'origine végétale, Capécitabine, Désoxycytidine, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique, Taxoïdes, Vinblastine.
- analogues et dérivés : Désoxycytidine, Vinblastine.
- anatomopathologie : Tumeurs du sein.
- effets indésirables : Antinéoplasiques antimétabolites, Antinéoplasiques d'origine végétale, Désoxycytidine, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique, Taxoïdes, Vinblastine.
- mortalité : Tumeurs du sein.
- métabolisme : Récepteur ErbB-2, Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques antimétabolites, Antinéoplasiques d'origine végétale, Capécitabine, Désoxycytidine, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique, Taxoïdes, Vinblastine.
- Administration par voie intraveineuse, Administration par voie orale, Adulte, Adulte d'âge moyen, Alopécie, Fatigue, Femelle, Humains, Neutropénie, Qualité de vie, Résultat thérapeutique, Sujet âgé, Survie sans rechute, Traitement néoadjuvant.
English descriptors
- KwdEn :
- Administration, Intravenous, Administration, Oral, Adult, Aged, Alopecia (chemically induced), Antimetabolites, Antineoplastic (administration & dosage), Antimetabolites, Antineoplastic (adverse effects), Antimetabolites, Antineoplastic (therapeutic use), Antineoplastic Agents, Phytogenic (administration & dosage), Antineoplastic Agents, Phytogenic (adverse effects), Antineoplastic Agents, Phytogenic (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Breast Neoplasms (drug therapy), Breast Neoplasms (metabolism), Breast Neoplasms (mortality), Breast Neoplasms (pathology), Capecitabine (administration & dosage), Capecitabine (therapeutic use), Deoxycytidine (administration & dosage), Deoxycytidine (adverse effects), Deoxycytidine (analogs & derivatives), Deoxycytidine (therapeutic use), Disease-Free Survival, Fatigue (chemically induced), Female, Humans, Middle Aged, Neoadjuvant Therapy (methods), Neutropenia (chemically induced), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Paclitaxel (therapeutic use), Quality of Life, Receptor, ErbB-2 (metabolism), Taxoids (administration & dosage), Taxoids (adverse effects), Taxoids (therapeutic use), Treatment Outcome, Vinblastine (administration & dosage), Vinblastine (adverse effects), Vinblastine (analogs & derivatives), Vinblastine (therapeutic use).
- MESH :
- chemical , administration & dosage : Antimetabolites, Antineoplastic, Antineoplastic Agents, Phytogenic, Capecitabine, Deoxycytidine, Paclitaxel, Taxoids, Vinblastine.
- chemical , adverse effects : Antimetabolites, Antineoplastic, Antineoplastic Agents, Phytogenic, Deoxycytidine, Paclitaxel, Taxoids, Vinblastine.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemical , analogs & derivatives : Deoxycytidine, Vinblastine.
- chemically induced : Alopecia, Fatigue, Neutropenia.
- drug therapy : Breast Neoplasms.
- metabolism : Breast Neoplasms, Receptor, ErbB-2.
- methods : Neoadjuvant Therapy.
- mortality : Breast Neoplasms.
- pathology : Breast Neoplasms.
- chemical , therapeutic use : Antimetabolites, Antineoplastic, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Deoxycytidine, Paclitaxel, Taxoids, Vinblastine.
- Administration, Intravenous, Administration, Oral, Adult, Aged, Disease-Free Survival, Female, Humans, Middle Aged, Quality of Life, Treatment Outcome.
Abstract
The purpose of this study was to evaluate the efficacy of 3 first-line chemotherapy combination regimens for HER2-negative metastatic breast cancer (mBC).
DOI: 10.1016/j.clbc.2016.06.014
PubMed: 27756583
Affiliations:
- Afrique du Sud, Argentine, Australie, Belgique, Espagne, France, Italie, Suisse, Turquie
- Catalogne, Limousin, Nouvelle-Aquitaine
- Barcelone, Limoges
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E93
- to stream PubMed, to step Curation: 000E90
- to stream PubMed, to step Checkpoint: 000E90
- to stream Ncbi, to step Merge: 003D30
- to stream Ncbi, to step Curation: 003D30
- to stream Ncbi, to step Checkpoint: 003D30
- to stream Main, to step Merge: 000C16
- to stream Main, to step Curation: 000C21
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.</title><author><name sortKey="Cinieri, Saverio" sort="Cinieri, Saverio" uniqKey="Cinieri S" first="Saverio" last="Cinieri">Saverio Cinieri</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan, and San Antonio Perrino Hospital, Brindisi, Italy. Electronic address: saverio.cinieri@ieo.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan, and San Antonio Perrino Hospital, Brindisi</wicri:regionArea><wicri:noRegion>Brindisi</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name><affiliation wicri:level="1"><nlm:affiliation>Breast Cancer Research Centre-WA and Curtin University, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Breast Cancer Research Centre-WA and Curtin University, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Altundag, Kadri" sort="Altundag, Kadri" uniqKey="Altundag K" first="Kadri" last="Altundag">Kadri Altundag</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Vandebroek, An" sort="Vandebroek, An" uniqKey="Vandebroek A" first="An" last="Vandebroek">An Vandebroek</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, ZNA Middelheim Hospital, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Medical Oncology Department, ZNA Middelheim Hospital, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Tubiana Mathieu, Nicole" sort="Tubiana Mathieu, Nicole" uniqKey="Tubiana Mathieu N" first="Nicole" last="Tubiana-Mathieu">Nicole Tubiana-Mathieu</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Universitaire de Limoges, Limoges, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier Universitaire de Limoges, Limoges</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Limousin</region><settlement type="city">Limoges</settlement></placeName></affiliation></author><author><name sortKey="Barnadas, Agusti" sort="Barnadas, Agusti" uniqKey="Barnadas A" first="Agusti" last="Barnadas">Agusti Barnadas</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Sant Pau, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Department, Hospital Sant Pau, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Dodyk, Patricia" sort="Dodyk, Patricia" uniqKey="Dodyk P" first="Patricia" last="Dodyk">Patricia Dodyk</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, CER Instituto Medico, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Medical Oncology Department, CER Instituto Medico, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Lazzarelli, Silvia" sort="Lazzarelli, Silvia" uniqKey="Lazzarelli S" first="Silvia" last="Lazzarelli">Silvia Lazzarelli</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, Istituti Ospitalieri di Cremona, Cremona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology Department, Istituti Ospitalieri di Cremona, Cremona</wicri:regionArea><wicri:noRegion>Cremona</wicri:noRegion></affiliation></author><author><name sortKey="Botha, Michiel" sort="Botha, Michiel" uniqKey="Botha M" first="Michiel" last="Botha">Michiel Botha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, National Hospital, Bloemfontein, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Oncology, National Hospital, Bloemfontein</wicri:regionArea><wicri:noRegion>Bloemfontein</wicri:noRegion></affiliation></author><author><name sortKey="Rauch, Daniel" sort="Rauch, Daniel" uniqKey="Rauch D" first="Daniel" last="Rauch">Daniel Rauch</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, Regionalspital Thun, Thun, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Medical Oncology Department, Regionalspital Thun, Thun</wicri:regionArea><wicri:noRegion>Thun</wicri:noRegion></affiliation></author><author><name sortKey="Villanova, Gustavo" sort="Villanova, Gustavo" uniqKey="Villanova G" first="Gustavo" last="Villanova">Gustavo Villanova</name><affiliation wicri:level="1"><nlm:affiliation>Medical Affairs Oncology, Institut de Recherche Pierre Fabre, Boulogne-Billancourt Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Affairs Oncology, Institut de Recherche Pierre Fabre, Boulogne-Billancourt Cedex</wicri:regionArea><wicri:noRegion>Boulogne-Billancourt Cedex</wicri:noRegion><wicri:noRegion>Boulogne-Billancourt Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Coskun, Ugur" sort="Coskun, Ugur" uniqKey="Coskun U" first="Ugur" last="Coskun">Ugur Coskun</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gazi University School of Medicine, Gazi Hospital, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Medical Oncology, Gazi University School of Medicine, Gazi Hospital, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27756583</idno><idno type="pmid">27756583</idno><idno type="doi">10.1016/j.clbc.2016.06.014</idno><idno type="wicri:Area/PubMed/Corpus">000E93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E93</idno><idno type="wicri:Area/PubMed/Curation">000E90</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E90</idno><idno type="wicri:Area/PubMed/Checkpoint">000E90</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E90</idno><idno type="wicri:Area/Ncbi/Merge">003D30</idno><idno type="wicri:Area/Ncbi/Curation">003D30</idno><idno type="wicri:Area/Ncbi/Checkpoint">003D30</idno><idno type="wicri:Area/Main/Merge">000C16</idno><idno type="wicri:Area/Main/Curation">000C21</idno><idno type="wicri:Area/Main/Exploration">000C21</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.</title><author><name sortKey="Cinieri, Saverio" sort="Cinieri, Saverio" uniqKey="Cinieri S" first="Saverio" last="Cinieri">Saverio Cinieri</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan, and San Antonio Perrino Hospital, Brindisi, Italy. Electronic address: saverio.cinieri@ieo.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan, and San Antonio Perrino Hospital, Brindisi</wicri:regionArea><wicri:noRegion>Brindisi</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name><affiliation wicri:level="1"><nlm:affiliation>Breast Cancer Research Centre-WA and Curtin University, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Breast Cancer Research Centre-WA and Curtin University, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Altundag, Kadri" sort="Altundag, Kadri" uniqKey="Altundag K" first="Kadri" last="Altundag">Kadri Altundag</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Vandebroek, An" sort="Vandebroek, An" uniqKey="Vandebroek A" first="An" last="Vandebroek">An Vandebroek</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, ZNA Middelheim Hospital, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Medical Oncology Department, ZNA Middelheim Hospital, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Tubiana Mathieu, Nicole" sort="Tubiana Mathieu, Nicole" uniqKey="Tubiana Mathieu N" first="Nicole" last="Tubiana-Mathieu">Nicole Tubiana-Mathieu</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Universitaire de Limoges, Limoges, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier Universitaire de Limoges, Limoges</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Limousin</region><settlement type="city">Limoges</settlement></placeName></affiliation></author><author><name sortKey="Barnadas, Agusti" sort="Barnadas, Agusti" uniqKey="Barnadas A" first="Agusti" last="Barnadas">Agusti Barnadas</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Sant Pau, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Department, Hospital Sant Pau, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Dodyk, Patricia" sort="Dodyk, Patricia" uniqKey="Dodyk P" first="Patricia" last="Dodyk">Patricia Dodyk</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, CER Instituto Medico, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Medical Oncology Department, CER Instituto Medico, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Lazzarelli, Silvia" sort="Lazzarelli, Silvia" uniqKey="Lazzarelli S" first="Silvia" last="Lazzarelli">Silvia Lazzarelli</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, Istituti Ospitalieri di Cremona, Cremona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology Department, Istituti Ospitalieri di Cremona, Cremona</wicri:regionArea><wicri:noRegion>Cremona</wicri:noRegion></affiliation></author><author><name sortKey="Botha, Michiel" sort="Botha, Michiel" uniqKey="Botha M" first="Michiel" last="Botha">Michiel Botha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, National Hospital, Bloemfontein, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Oncology, National Hospital, Bloemfontein</wicri:regionArea><wicri:noRegion>Bloemfontein</wicri:noRegion></affiliation></author><author><name sortKey="Rauch, Daniel" sort="Rauch, Daniel" uniqKey="Rauch D" first="Daniel" last="Rauch">Daniel Rauch</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, Regionalspital Thun, Thun, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Medical Oncology Department, Regionalspital Thun, Thun</wicri:regionArea><wicri:noRegion>Thun</wicri:noRegion></affiliation></author><author><name sortKey="Villanova, Gustavo" sort="Villanova, Gustavo" uniqKey="Villanova G" first="Gustavo" last="Villanova">Gustavo Villanova</name><affiliation wicri:level="1"><nlm:affiliation>Medical Affairs Oncology, Institut de Recherche Pierre Fabre, Boulogne-Billancourt Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Affairs Oncology, Institut de Recherche Pierre Fabre, Boulogne-Billancourt Cedex</wicri:regionArea><wicri:noRegion>Boulogne-Billancourt Cedex</wicri:noRegion><wicri:noRegion>Boulogne-Billancourt Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Coskun, Ugur" sort="Coskun, Ugur" uniqKey="Coskun U" first="Ugur" last="Coskun">Ugur Coskun</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gazi University School of Medicine, Gazi Hospital, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Medical Oncology, Gazi University School of Medicine, Gazi Hospital, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical breast cancer</title><idno type="eISSN">1938-0666</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Alopecia (chemically induced)</term><term>Antimetabolites, Antineoplastic (administration & dosage)</term><term>Antimetabolites, Antineoplastic (adverse effects)</term><term>Antimetabolites, Antineoplastic (therapeutic use)</term><term>Antineoplastic Agents, Phytogenic (administration & dosage)</term><term>Antineoplastic Agents, Phytogenic (adverse effects)</term><term>Antineoplastic Agents, Phytogenic (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (metabolism)</term><term>Breast Neoplasms (mortality)</term><term>Breast Neoplasms (pathology)</term><term>Capecitabine (administration & dosage)</term><term>Capecitabine (therapeutic use)</term><term>Deoxycytidine (administration & dosage)</term><term>Deoxycytidine (adverse effects)</term><term>Deoxycytidine (analogs & derivatives)</term><term>Deoxycytidine (therapeutic use)</term><term>Disease-Free Survival</term><term>Fatigue (chemically induced)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Neoadjuvant Therapy (methods)</term><term>Neutropenia (chemically induced)</term><term>Paclitaxel (administration & dosage)</term><term>Paclitaxel (adverse effects)</term><term>Paclitaxel (therapeutic use)</term><term>Quality of Life</term><term>Receptor, ErbB-2 (metabolism)</term><term>Taxoids (administration & dosage)</term><term>Taxoids (adverse effects)</term><term>Taxoids (therapeutic use)</term><term>Treatment Outcome</term><term>Vinblastine (administration & dosage)</term><term>Vinblastine (adverse effects)</term><term>Vinblastine (analogs & derivatives)</term><term>Vinblastine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Administration par voie orale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Alopécie ()</term><term>Antinéoplasiques antimétabolites (administration et posologie)</term><term>Antinéoplasiques antimétabolites (effets indésirables)</term><term>Antinéoplasiques antimétabolites (usage thérapeutique)</term><term>Antinéoplasiques d'origine végétale (administration et posologie)</term><term>Antinéoplasiques d'origine végétale (effets indésirables)</term><term>Antinéoplasiques d'origine végétale (usage thérapeutique)</term><term>Capécitabine (administration et posologie)</term><term>Capécitabine (usage thérapeutique)</term><term>Désoxycytidine (administration et posologie)</term><term>Désoxycytidine (analogues et dérivés)</term><term>Désoxycytidine (effets indésirables)</term><term>Désoxycytidine (usage thérapeutique)</term><term>Fatigue ()</term><term>Femelle</term><term>Humains</term><term>Neutropénie ()</term><term>Paclitaxel (administration et posologie)</term><term>Paclitaxel (effets indésirables)</term><term>Paclitaxel (usage thérapeutique)</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Qualité de vie</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Taxoïdes (administration et posologie)</term><term>Taxoïdes (effets indésirables)</term><term>Taxoïdes (usage thérapeutique)</term><term>Traitement néoadjuvant ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (mortalité)</term><term>Tumeurs du sein (métabolisme)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Vinblastine (administration et posologie)</term><term>Vinblastine (analogues et dérivés)</term><term>Vinblastine (effets indésirables)</term><term>Vinblastine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Antineoplastic Agents, Phytogenic</term><term>Capecitabine</term><term>Deoxycytidine</term><term>Paclitaxel</term><term>Taxoids</term><term>Vinblastine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Antineoplastic Agents, Phytogenic</term><term>Deoxycytidine</term><term>Paclitaxel</term><term>Taxoids</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Antinéoplasiques d'origine végétale</term><term>Capécitabine</term><term>Désoxycytidine</term><term>Paclitaxel</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Taxoïdes</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Alopecia</term><term>Fatigue</term><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Antinéoplasiques d'origine végétale</term><term>Désoxycytidine</term><term>Paclitaxel</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Taxoïdes</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Neoadjuvant Therapy</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteur ErbB-2</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Antineoplastic Agents, Phytogenic</term><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Capecitabine</term><term>Deoxycytidine</term><term>Paclitaxel</term><term>Taxoids</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Antinéoplasiques d'origine végétale</term><term>Capécitabine</term><term>Désoxycytidine</term><term>Paclitaxel</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Taxoïdes</term><term>Vinblastine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Administration par voie orale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Alopécie</term><term>Fatigue</term><term>Femelle</term><term>Humains</term><term>Neutropénie</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Traitement néoadjuvant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this study was to evaluate the efficacy of 3 first-line chemotherapy combination regimens for HER2-negative metastatic breast cancer (mBC).</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Argentine</li><li>Australie</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Italie</li><li>Suisse</li><li>Turquie</li></country><region><li>Catalogne</li><li>Limousin</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Barcelone</li><li>Limoges</li></settlement></list><tree><country name="Italie"><noRegion><name sortKey="Cinieri, Saverio" sort="Cinieri, Saverio" uniqKey="Cinieri S" first="Saverio" last="Cinieri">Saverio Cinieri</name></noRegion><name sortKey="Lazzarelli, Silvia" sort="Lazzarelli, Silvia" uniqKey="Lazzarelli S" first="Silvia" last="Lazzarelli">Silvia Lazzarelli</name></country><country name="Australie"><noRegion><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name></noRegion></country><country name="Turquie"><noRegion><name sortKey="Altundag, Kadri" sort="Altundag, Kadri" uniqKey="Altundag K" first="Kadri" last="Altundag">Kadri Altundag</name></noRegion><name sortKey="Coskun, Ugur" sort="Coskun, Ugur" uniqKey="Coskun U" first="Ugur" last="Coskun">Ugur Coskun</name></country><country name="Belgique"><noRegion><name sortKey="Vandebroek, An" sort="Vandebroek, An" uniqKey="Vandebroek A" first="An" last="Vandebroek">An Vandebroek</name></noRegion></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Tubiana Mathieu, Nicole" sort="Tubiana Mathieu, Nicole" uniqKey="Tubiana Mathieu N" first="Nicole" last="Tubiana-Mathieu">Nicole Tubiana-Mathieu</name></region><name sortKey="Villanova, Gustavo" sort="Villanova, Gustavo" uniqKey="Villanova G" first="Gustavo" last="Villanova">Gustavo Villanova</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Barnadas, Agusti" sort="Barnadas, Agusti" uniqKey="Barnadas A" first="Agusti" last="Barnadas">Agusti Barnadas</name></region></country><country name="Argentine"><noRegion><name sortKey="Dodyk, Patricia" sort="Dodyk, Patricia" uniqKey="Dodyk P" first="Patricia" last="Dodyk">Patricia Dodyk</name></noRegion></country><country name="Afrique du Sud"><noRegion><name sortKey="Botha, Michiel" sort="Botha, Michiel" uniqKey="Botha M" first="Michiel" last="Botha">Michiel Botha</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Rauch, Daniel" sort="Rauch, Daniel" uniqKey="Rauch D" first="Daniel" last="Rauch">Daniel Rauch</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27756583
|texte= Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27756583" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |